The traditional “bottom-up” approach to drug discovery is not best equipped to translate these unprecedented insights into the next wave of new medicines.
LifeMine is pioneering a bold new approach, Top-Down Drug DiscoveryTM, which leverages evolutionary insights from fungi to unearth next-generation precision medicines.
Through our data-immersive and technologically expansive discovery engine, we are bringing sophisticated medicines to patients in urgent need of breakthrough disease intervention.
We are uniquely positioned to discover mechanistically and structurally novel precision medicines against high-impact disease targets faster than ever before. Our initial pipeline programs are focused in organ transplantation and antifungals: two areas waiting to be revolutionized with better medicines.
Backed by leading life sciences investors, LifeMine is a fast-growing company. We are looking for top talent who share in our passion for groundbreaking science and commitment to advancing next-generation precision medicines.
For biotech entrepreneur Greg Verdine, opportunity just kept knocking
Escaping an improbable upbringing, Greg Verdine places his biggest career bets in drugging the ‘undruggable’
LifeMine Therapeutics Appoints Elliot Ehrich, M.D., as Chief Medical Officer and EVP of Translational Science and Lata Jayaraman, Ph.D., as EVP, Head of Biology
Top 50 medium-size employers in Massachusetts for 2022
